Loading…
Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study
In this study, we investigated the causes of death and the factors associated with mortality in a cohort of patients receiving highly active antiretroviral therapy (HAART) in Burkina Faso, an African country with limited resources. This retrospective cohort study included patients aged 15 years and...
Saved in:
Published in: | AIDS care 2012-04, Vol.24 (4), p.478-490 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c518t-bd49ac5b6b3ba033190e3cbe87e8e5d1342b2ad43c594efa6b534fc4d33a0a1e3 |
---|---|
cites | cdi_FETCH-LOGICAL-c518t-bd49ac5b6b3ba033190e3cbe87e8e5d1342b2ad43c594efa6b534fc4d33a0a1e3 |
container_end_page | 490 |
container_issue | 4 |
container_start_page | 478 |
container_title | AIDS care |
container_volume | 24 |
creator | Kouanda, S. Meda, I.B. Nikiema, L. Tiendrebeogo, S. Doulougou, B. Kaboré, I. Sanou, M.J. Greenwell, F. Soudré, R. Sondo, B. |
description | In this study, we investigated the causes of death and the factors associated with mortality in a cohort of patients receiving highly active antiretroviral therapy (HAART) in Burkina Faso, an African country with limited resources. This retrospective cohort study included patients aged 15 years and older who started HAART for the first time between January 2003 and December 2008 in 14 health districts. We used survival analyses, including the Kaplan-Meier method, to examine potential predictors of death and two Cox proportional hazard models to estimate hazard ratios for death, first from baseline covariates and then from time-dependent covariates. A total of 6641 patients initiated HAART during this period; of these, 5608 were included in the analysis. By the end of the study period, 4310 of those patients were still receiving HAART, 690 had died, 207 had been transferred and 401 were lost to follow-up. The median duration of follow-up was 23.2 months [interquartile range (IQR): 12.4-36.9], and the overall incidence of mortality was 6 per 100 person-years. The clinical stage, CD4 count, body mass index (BMI), haemoglobin level, HAART regimen, gender, age, profession and year of initiation were the primary risk factors associated with death. In the multivariate analysis, BMI, clinical stage, treatment regimen and CD4 count remained significantly associated with death. The most frequent causes of death were wasting syndrome, tuberculosis and anaemia. This result highlights the already advanced stage of immunodeficiency among patients in Burkina Faso when they start HAART. Testing patients for HIV and starting antiretroviral therapy earlier are necessary to further reduce the mortality of patients living with HIV. This study provides a solid evidence base with which future evaluations of HAART in Burkina Faso can be compared. |
doi_str_mv | 10.1080/09540121.2011.630353 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1114286296</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1291617784</sourcerecordid><originalsourceid>FETCH-LOGICAL-c518t-bd49ac5b6b3ba033190e3cbe87e8e5d1342b2ad43c594efa6b534fc4d33a0a1e3</originalsourceid><addsrcrecordid>eNqF0lFr1TAYBuAiijtO_4FIEGTe9Jg0SZt4I246Nxh4o96Wr-lXl9k2xyQ90j_i7zXdOUfBi-2qEJ73bQhvlj1ndM2oom-oloKygq0Lyti65JRL_iBbMV7SnArJHmarheSLOcqehHBDKS1oSR9nR0XBhNIVX2W_P2BEP9gRxhgIjC0xMAUMxHVkcD5Cb-NM7EguLr_lduzQRGzJBqLFJeDRoN3a8XuKRusxere1HnoSr9HD5jZ5OvkfqZ-cQ3BvCZDObjGfETy59WGTOtMRMe46_ZCEOLXz0-xRB33AZ_vvcfb1_OOXs4v86vOny7P3V7mRTMW8aYUGI5uy4Q1QzpmmyE2DqkKFsmVcFE0BreBGaoEdlI3kojOi5RwoMOTH2cmud-PdzwlDrAcbDPY9jOimUGvNNVWlpEm-vlMyzqRKklf300KzklWVEvdTxkShykKXib78j964yY_pddItpagklUuf2CGTHjZ47OqNtwP4uWa0XmZTH2ZTL7Opd7NJsRf77qkZsP0bOuwkgVd7AMFA33kYjQ3_nKyU1lol927n0lScH-CX831bR5h75w8hfudV_gAPD99u</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>995475054</pqid></control><display><type>article</type><title>Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>International Bibliography of the Social Sciences (IBSS)</source><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Kouanda, S. ; Meda, I.B. ; Nikiema, L. ; Tiendrebeogo, S. ; Doulougou, B. ; Kaboré, I. ; Sanou, M.J. ; Greenwell, F. ; Soudré, R. ; Sondo, B.</creator><creatorcontrib>Kouanda, S. ; Meda, I.B. ; Nikiema, L. ; Tiendrebeogo, S. ; Doulougou, B. ; Kaboré, I. ; Sanou, M.J. ; Greenwell, F. ; Soudré, R. ; Sondo, B.</creatorcontrib><description>In this study, we investigated the causes of death and the factors associated with mortality in a cohort of patients receiving highly active antiretroviral therapy (HAART) in Burkina Faso, an African country with limited resources. This retrospective cohort study included patients aged 15 years and older who started HAART for the first time between January 2003 and December 2008 in 14 health districts. We used survival analyses, including the Kaplan-Meier method, to examine potential predictors of death and two Cox proportional hazard models to estimate hazard ratios for death, first from baseline covariates and then from time-dependent covariates. A total of 6641 patients initiated HAART during this period; of these, 5608 were included in the analysis. By the end of the study period, 4310 of those patients were still receiving HAART, 690 had died, 207 had been transferred and 401 were lost to follow-up. The median duration of follow-up was 23.2 months [interquartile range (IQR): 12.4-36.9], and the overall incidence of mortality was 6 per 100 person-years. The clinical stage, CD4 count, body mass index (BMI), haemoglobin level, HAART regimen, gender, age, profession and year of initiation were the primary risk factors associated with death. In the multivariate analysis, BMI, clinical stage, treatment regimen and CD4 count remained significantly associated with death. The most frequent causes of death were wasting syndrome, tuberculosis and anaemia. This result highlights the already advanced stage of immunodeficiency among patients in Burkina Faso when they start HAART. Testing patients for HIV and starting antiretroviral therapy earlier are necessary to further reduce the mortality of patients living with HIV. This study provides a solid evidence base with which future evaluations of HAART in Burkina Faso can be compared.</description><identifier>ISSN: 0954-0121</identifier><identifier>EISSN: 1360-0451</identifier><identifier>DOI: 10.1080/09540121.2011.630353</identifier><identifier>PMID: 22148973</identifier><identifier>CODEN: AIDCEF</identifier><language>eng</language><publisher>Abingdon: Taylor & Francis Group</publisher><subject>Adolescent ; Adult ; Age Factors ; AIDS ; AIDS/HIV ; Antiretroviral drugs ; Antiretroviral therapy ; Antiretroviral Therapy, Highly Active - methods ; Antiretroviral Therapy, Highly Active - statistics & numerical data ; Biological and medical sciences ; Body Mass Index ; Burkina Faso ; Burkina Faso - epidemiology ; Cause of Death ; CD4 Lymphocyte Count ; Cohort analysis ; Death ; Drug therapy ; Female ; HAART ; Hemoglobins - analysis ; HIV ; HIV Infections - diagnosis ; HIV Infections - drug therapy ; HIV Infections - mortality ; Human immunodeficiency virus ; Human viral diseases ; Humans ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunopathology ; Infectious diseases ; Kaplan-Meier Estimate ; Male ; Medical sciences ; Medical treatment ; Middle Aged ; Mortality ; Mycobacterium ; Patients ; predictors ; Proportional Hazards Models ; Retrospective Studies ; Risk ; Risk Factors ; Sex Factors ; Survival analysis ; Treatment Outcome ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids</subject><ispartof>AIDS care, 2012-04, Vol.24 (4), p.478-490</ispartof><rights>Copyright Taylor & Francis Group, LLC 2012</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Taylor & Francis Ltd. 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c518t-bd49ac5b6b3ba033190e3cbe87e8e5d1342b2ad43c594efa6b534fc4d33a0a1e3</citedby><cites>FETCH-LOGICAL-c518t-bd49ac5b6b3ba033190e3cbe87e8e5d1342b2ad43c594efa6b534fc4d33a0a1e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,30999,31000,33223,33224</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25789998$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22148973$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kouanda, S.</creatorcontrib><creatorcontrib>Meda, I.B.</creatorcontrib><creatorcontrib>Nikiema, L.</creatorcontrib><creatorcontrib>Tiendrebeogo, S.</creatorcontrib><creatorcontrib>Doulougou, B.</creatorcontrib><creatorcontrib>Kaboré, I.</creatorcontrib><creatorcontrib>Sanou, M.J.</creatorcontrib><creatorcontrib>Greenwell, F.</creatorcontrib><creatorcontrib>Soudré, R.</creatorcontrib><creatorcontrib>Sondo, B.</creatorcontrib><title>Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study</title><title>AIDS care</title><addtitle>AIDS Care</addtitle><description>In this study, we investigated the causes of death and the factors associated with mortality in a cohort of patients receiving highly active antiretroviral therapy (HAART) in Burkina Faso, an African country with limited resources. This retrospective cohort study included patients aged 15 years and older who started HAART for the first time between January 2003 and December 2008 in 14 health districts. We used survival analyses, including the Kaplan-Meier method, to examine potential predictors of death and two Cox proportional hazard models to estimate hazard ratios for death, first from baseline covariates and then from time-dependent covariates. A total of 6641 patients initiated HAART during this period; of these, 5608 were included in the analysis. By the end of the study period, 4310 of those patients were still receiving HAART, 690 had died, 207 had been transferred and 401 were lost to follow-up. The median duration of follow-up was 23.2 months [interquartile range (IQR): 12.4-36.9], and the overall incidence of mortality was 6 per 100 person-years. The clinical stage, CD4 count, body mass index (BMI), haemoglobin level, HAART regimen, gender, age, profession and year of initiation were the primary risk factors associated with death. In the multivariate analysis, BMI, clinical stage, treatment regimen and CD4 count remained significantly associated with death. The most frequent causes of death were wasting syndrome, tuberculosis and anaemia. This result highlights the already advanced stage of immunodeficiency among patients in Burkina Faso when they start HAART. Testing patients for HIV and starting antiretroviral therapy earlier are necessary to further reduce the mortality of patients living with HIV. This study provides a solid evidence base with which future evaluations of HAART in Burkina Faso can be compared.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age Factors</subject><subject>AIDS</subject><subject>AIDS/HIV</subject><subject>Antiretroviral drugs</subject><subject>Antiretroviral therapy</subject><subject>Antiretroviral Therapy, Highly Active - methods</subject><subject>Antiretroviral Therapy, Highly Active - statistics & numerical data</subject><subject>Biological and medical sciences</subject><subject>Body Mass Index</subject><subject>Burkina Faso</subject><subject>Burkina Faso - epidemiology</subject><subject>Cause of Death</subject><subject>CD4 Lymphocyte Count</subject><subject>Cohort analysis</subject><subject>Death</subject><subject>Drug therapy</subject><subject>Female</subject><subject>HAART</subject><subject>Hemoglobins - analysis</subject><subject>HIV</subject><subject>HIV Infections - diagnosis</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - mortality</subject><subject>Human immunodeficiency virus</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Infectious diseases</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medical treatment</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Mycobacterium</subject><subject>Patients</subject><subject>predictors</subject><subject>Proportional Hazards Models</subject><subject>Retrospective Studies</subject><subject>Risk</subject><subject>Risk Factors</subject><subject>Sex Factors</subject><subject>Survival analysis</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><issn>0954-0121</issn><issn>1360-0451</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><sourceid>8BJ</sourceid><recordid>eNqF0lFr1TAYBuAiijtO_4FIEGTe9Jg0SZt4I246Nxh4o96Wr-lXl9k2xyQ90j_i7zXdOUfBi-2qEJ73bQhvlj1ndM2oom-oloKygq0Lyti65JRL_iBbMV7SnArJHmarheSLOcqehHBDKS1oSR9nR0XBhNIVX2W_P2BEP9gRxhgIjC0xMAUMxHVkcD5Cb-NM7EguLr_lduzQRGzJBqLFJeDRoN3a8XuKRusxere1HnoSr9HD5jZ5OvkfqZ-cQ3BvCZDObjGfETy59WGTOtMRMe46_ZCEOLXz0-xRB33AZ_vvcfb1_OOXs4v86vOny7P3V7mRTMW8aYUGI5uy4Q1QzpmmyE2DqkKFsmVcFE0BreBGaoEdlI3kojOi5RwoMOTH2cmud-PdzwlDrAcbDPY9jOimUGvNNVWlpEm-vlMyzqRKklf300KzklWVEvdTxkShykKXib78j964yY_pddItpagklUuf2CGTHjZ47OqNtwP4uWa0XmZTH2ZTL7Opd7NJsRf77qkZsP0bOuwkgVd7AMFA33kYjQ3_nKyU1lol927n0lScH-CX831bR5h75w8hfudV_gAPD99u</recordid><startdate>20120401</startdate><enddate>20120401</enddate><creator>Kouanda, S.</creator><creator>Meda, I.B.</creator><creator>Nikiema, L.</creator><creator>Tiendrebeogo, S.</creator><creator>Doulougou, B.</creator><creator>Kaboré, I.</creator><creator>Sanou, M.J.</creator><creator>Greenwell, F.</creator><creator>Soudré, R.</creator><creator>Sondo, B.</creator><general>Taylor & Francis Group</general><general>Taylor & Francis</general><general>Taylor & Francis Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U9</scope><scope>8BJ</scope><scope>8FD</scope><scope>C1K</scope><scope>FQK</scope><scope>FR3</scope><scope>H94</scope><scope>JBE</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7U1</scope><scope>7U2</scope><scope>7X8</scope></search><sort><creationdate>20120401</creationdate><title>Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study</title><author>Kouanda, S. ; Meda, I.B. ; Nikiema, L. ; Tiendrebeogo, S. ; Doulougou, B. ; Kaboré, I. ; Sanou, M.J. ; Greenwell, F. ; Soudré, R. ; Sondo, B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c518t-bd49ac5b6b3ba033190e3cbe87e8e5d1342b2ad43c594efa6b534fc4d33a0a1e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age Factors</topic><topic>AIDS</topic><topic>AIDS/HIV</topic><topic>Antiretroviral drugs</topic><topic>Antiretroviral therapy</topic><topic>Antiretroviral Therapy, Highly Active - methods</topic><topic>Antiretroviral Therapy, Highly Active - statistics & numerical data</topic><topic>Biological and medical sciences</topic><topic>Body Mass Index</topic><topic>Burkina Faso</topic><topic>Burkina Faso - epidemiology</topic><topic>Cause of Death</topic><topic>CD4 Lymphocyte Count</topic><topic>Cohort analysis</topic><topic>Death</topic><topic>Drug therapy</topic><topic>Female</topic><topic>HAART</topic><topic>Hemoglobins - analysis</topic><topic>HIV</topic><topic>HIV Infections - diagnosis</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - mortality</topic><topic>Human immunodeficiency virus</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Infectious diseases</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medical treatment</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Mycobacterium</topic><topic>Patients</topic><topic>predictors</topic><topic>Proportional Hazards Models</topic><topic>Retrospective Studies</topic><topic>Risk</topic><topic>Risk Factors</topic><topic>Sex Factors</topic><topic>Survival analysis</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kouanda, S.</creatorcontrib><creatorcontrib>Meda, I.B.</creatorcontrib><creatorcontrib>Nikiema, L.</creatorcontrib><creatorcontrib>Tiendrebeogo, S.</creatorcontrib><creatorcontrib>Doulougou, B.</creatorcontrib><creatorcontrib>Kaboré, I.</creatorcontrib><creatorcontrib>Sanou, M.J.</creatorcontrib><creatorcontrib>Greenwell, F.</creatorcontrib><creatorcontrib>Soudré, R.</creatorcontrib><creatorcontrib>Sondo, B.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>International Bibliography of the Social Sciences (IBSS)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>International Bibliography of the Social Sciences</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>International Bibliography of the Social Sciences</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>MEDLINE - Academic</collection><jtitle>AIDS care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kouanda, S.</au><au>Meda, I.B.</au><au>Nikiema, L.</au><au>Tiendrebeogo, S.</au><au>Doulougou, B.</au><au>Kaboré, I.</au><au>Sanou, M.J.</au><au>Greenwell, F.</au><au>Soudré, R.</au><au>Sondo, B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study</atitle><jtitle>AIDS care</jtitle><addtitle>AIDS Care</addtitle><date>2012-04-01</date><risdate>2012</risdate><volume>24</volume><issue>4</issue><spage>478</spage><epage>490</epage><pages>478-490</pages><issn>0954-0121</issn><eissn>1360-0451</eissn><coden>AIDCEF</coden><abstract>In this study, we investigated the causes of death and the factors associated with mortality in a cohort of patients receiving highly active antiretroviral therapy (HAART) in Burkina Faso, an African country with limited resources. This retrospective cohort study included patients aged 15 years and older who started HAART for the first time between January 2003 and December 2008 in 14 health districts. We used survival analyses, including the Kaplan-Meier method, to examine potential predictors of death and two Cox proportional hazard models to estimate hazard ratios for death, first from baseline covariates and then from time-dependent covariates. A total of 6641 patients initiated HAART during this period; of these, 5608 were included in the analysis. By the end of the study period, 4310 of those patients were still receiving HAART, 690 had died, 207 had been transferred and 401 were lost to follow-up. The median duration of follow-up was 23.2 months [interquartile range (IQR): 12.4-36.9], and the overall incidence of mortality was 6 per 100 person-years. The clinical stage, CD4 count, body mass index (BMI), haemoglobin level, HAART regimen, gender, age, profession and year of initiation were the primary risk factors associated with death. In the multivariate analysis, BMI, clinical stage, treatment regimen and CD4 count remained significantly associated with death. The most frequent causes of death were wasting syndrome, tuberculosis and anaemia. This result highlights the already advanced stage of immunodeficiency among patients in Burkina Faso when they start HAART. Testing patients for HIV and starting antiretroviral therapy earlier are necessary to further reduce the mortality of patients living with HIV. This study provides a solid evidence base with which future evaluations of HAART in Burkina Faso can be compared.</abstract><cop>Abingdon</cop><pub>Taylor & Francis Group</pub><pmid>22148973</pmid><doi>10.1080/09540121.2011.630353</doi><tpages>13</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0954-0121 |
ispartof | AIDS care, 2012-04, Vol.24 (4), p.478-490 |
issn | 0954-0121 1360-0451 |
language | eng |
recordid | cdi_proquest_miscellaneous_1114286296 |
source | Applied Social Sciences Index & Abstracts (ASSIA); International Bibliography of the Social Sciences (IBSS); Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
subjects | Adolescent Adult Age Factors AIDS AIDS/HIV Antiretroviral drugs Antiretroviral therapy Antiretroviral Therapy, Highly Active - methods Antiretroviral Therapy, Highly Active - statistics & numerical data Biological and medical sciences Body Mass Index Burkina Faso Burkina Faso - epidemiology Cause of Death CD4 Lymphocyte Count Cohort analysis Death Drug therapy Female HAART Hemoglobins - analysis HIV HIV Infections - diagnosis HIV Infections - drug therapy HIV Infections - mortality Human immunodeficiency virus Human viral diseases Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infectious diseases Kaplan-Meier Estimate Male Medical sciences Medical treatment Middle Aged Mortality Mycobacterium Patients predictors Proportional Hazards Models Retrospective Studies Risk Risk Factors Sex Factors Survival analysis Treatment Outcome Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids |
title | Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T17%3A02%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Determinants%20and%20causes%20of%20mortality%20in%20HIV-infected%20patients%20receiving%20antiretroviral%20therapy%20in%20Burkina%20Faso:%20a%20five-year%20retrospective%20cohort%20study&rft.jtitle=AIDS%20care&rft.au=Kouanda,%20S.&rft.date=2012-04-01&rft.volume=24&rft.issue=4&rft.spage=478&rft.epage=490&rft.pages=478-490&rft.issn=0954-0121&rft.eissn=1360-0451&rft.coden=AIDCEF&rft_id=info:doi/10.1080/09540121.2011.630353&rft_dat=%3Cproquest_cross%3E1291617784%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c518t-bd49ac5b6b3ba033190e3cbe87e8e5d1342b2ad43c594efa6b534fc4d33a0a1e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=995475054&rft_id=info:pmid/22148973&rfr_iscdi=true |